BioMarin Pharmaceutical Inc. - Product Pipeline Review - 2014

Published: Mar, 2014 | Pages: 68 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

BioMarin Pharmaceutical Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'BioMarin Pharmaceutical Inc. - Product Pipeline Review - 2014', provides an overview of the BioMarin Pharmaceutical Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of BioMarin Pharmaceutical Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of BioMarin Pharmaceutical Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of BioMarin Pharmaceutical Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the BioMarin Pharmaceutical Inc.'s pipeline products

Reasons to buy

- Evaluate BioMarin Pharmaceutical Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of BioMarin Pharmaceutical Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the BioMarin Pharmaceutical Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of BioMarin Pharmaceutical Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of BioMarin Pharmaceutical Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of BioMarin Pharmaceutical Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
BioMarin Pharmaceutical Inc. Snapshot 6
BioMarin Pharmaceutical Inc. Overview 6
Key Information 6
Key Facts 6
BioMarin Pharmaceutical Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
BioMarin Pharmaceutical Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
BioMarin Pharmaceutical Inc. - Pipeline Products Glance 14
BioMarin Pharmaceutical Inc. - Late Stage Pipeline Products 14
Pre-Registration Products/Combination Treatment Modalities 14
Phase III Products/Combination Treatment Modalities 15
BioMarin Pharmaceutical Inc. - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
BioMarin Pharmaceutical Inc. - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
BioMarin Pharmaceutical Inc. - Drug Profiles 20
elosulfase alfa 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
amifampridine 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
BMN-165 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
BMN-673 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
BMN-701 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
sapropterin dihydrochloride 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
BMN-111 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
BMN-190 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
RG-2833 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
BMN-103 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
BMN-250 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
BMN-270 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Chondroitin Sulfate Modulators For Spinal Cord Injury 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Heparan Sulfate Synthesis Inhibitor Program 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
RG-3250 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
RGFP-109 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Drug For Pathogenic Angiogenesis 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
BioMarin Pharmaceutical Inc. - Pipeline Analysis 43
BioMarin Pharmaceutical Inc. - Pipeline Products by Target 43
BioMarin Pharmaceutical Inc. - Pipeline Products by Route of Administration 45
BioMarin Pharmaceutical Inc. - Pipeline Products by Molecule Type 46
BioMarin Pharmaceutical Inc. - Pipeline Products by Mechanism of Action 47
BioMarin Pharmaceutical Inc. - Recent Pipeline Updates 49
BioMarin Pharmaceutical Inc. - Dormant Projects 62
BioMarin Pharmaceutical Inc. - Company Statement 63
BioMarin Pharmaceutical Inc. - Locations And Subsidiaries 65
Head Office 65
Other Locations & Subsidiaries 65
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 68
Disclaimer 68

List of Tables
BioMarin Pharmaceutical Inc., Key Information 6
BioMarin Pharmaceutical Inc., Key Facts 6
BioMarin Pharmaceutical Inc. - Pipeline by Indication, 2014 9
BioMarin Pharmaceutical Inc. - Pipeline by Stage of Development, 2014 10
BioMarin Pharmaceutical Inc. - Monotherapy Products in Pipeline, 2014 11
BioMarin Pharmaceutical Inc. - Partnered Products in Pipeline, 2014 12
BioMarin Pharmaceutical Inc. - Partnered Products/ Combination Treatment Modalities, 2014 13
BioMarin Pharmaceutical Inc. - Pre-Registration, 2014 14
BioMarin Pharmaceutical Inc. - Phase III, 2014 15
BioMarin Pharmaceutical Inc. - Phase II, 2014 16
BioMarin Pharmaceutical Inc. - Phase I, 2014 17
BioMarin Pharmaceutical Inc. - Preclinical, 2014 18
BioMarin Pharmaceutical Inc. - Discovery, 2014 19
BioMarin Pharmaceutical Inc. - Pipeline by Target, 2014 44
BioMarin Pharmaceutical Inc. - Pipeline by Route of Administration, 2014 45
BioMarin Pharmaceutical Inc. - Pipeline by Molecule Type, 2014 46
BioMarin Pharmaceutical Inc. - Pipeline Products by Mechanism of Action, 2014 48
BioMarin Pharmaceutical Inc. - Recent Pipeline Updates, 2014 49
BioMarin Pharmaceutical Inc. - Dormant Developmental Projects,2014 62
BioMarin Pharmaceutical Inc., Other Locations 65
BioMarin Pharmaceutical Inc., Subsidiaries 66